We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 51

Biovail v. Apotex; merits of 55.2 proceeding; metformin
  • Gowling WLG
  • Canada
  • February 12 2010

The Court dismissed the application for prohibition


Apotex v. Sanofi; interlocutory motion re: affidavits of documents; clopidogrel
  • Gowling WLG
  • Canada
  • February 12 2010

Both parties brought motions for further and better affidavits of documents


AstraZeneca v. Apotex; interlocutory motion for reply evidence; esomeprazole
  • Gowling WLG
  • Canada
  • February 12 2010

The Court dismissed AstraZeneca's appeal from the order of a prothonotary refusing to strike parts of Apotex' evidence and refusing to permit the applicants to file reply


Janssen-Ortho v. Apotex; interlocutory motion for reply evidence; methylphenidate
  • Gowling WLG
  • Canada
  • February 12 2010

In two NOC proceedings, the order of evidence was reversed


Federal Court of Appeal upholds denial of innovator profits and refuses to grant damages for future lost market share in first case under s. 8 of the PM(NOC) Regulations
  • Gowling WLG
  • Canada
  • June 5 2009

In September 2008, the Federal Court released its first decision interpreting s. 8 of the PM(NOC) Regulations


Canada (Attorney General) v. Celgene Corporation, appeal of a PMPRB decision
  • Gowling WLG
  • Canada
  • January 20 2010

The Court of Appeal overturned the decision of the Trial Judge and restored the decision of the PMPRB providing jurisdiction to the PMPRB over medicines imported under the Special Access Program


Sanofi-Aventis v. ApotexNovopharmRiva, interlocutory motion to consolidate actions
  • Gowling WLG
  • Canada
  • January 20 2010

Sanofi brought a motion to consolidate three actions pertaining to damages pursuant to section 8 of the NOC Regulations


Pfizer v. Pharmascience, merits of NOC proceeding
  • Gowling WLG
  • Canada
  • January 20 2010

The Court granted prohibition to Pfizer and found that Pharmascience’s allegations of invalidity were not justified


Schering v. Pharmascience, merits of NOC proceeding
  • Gowling WLG
  • Canada
  • January 20 2010

The application under the NOC Regulations was dismissed


Apotex v. Pfizer
  • Gowling WLG
  • Canada
  • March 4 2009

The Court of Appeal dismissed the generic company's appeal and upheld the decision of the trial judge prohibiting Apotex entering the market until the expiry of the patent